First, we investigated the levels of FOXM1 in 93 human pancreatic cancer tissue samples using immunohistochemical analysis; all these patients received gemcitabine-based monotherapy (n=57, 61.3%) or combined chemotherapy (n=36, 38.7%). The gene discussed is FOXM1; the disease is familial pancreatic carcinoma.